A heat-inactivated H7N3 vaccine induces cross-reactive cellular immunity in HLA-A2.1 transgenic mice by Giuseppina Di Mario et al.
RESEARCH Open Access
A heat-inactivated H7N3 vaccine induces
cross-reactive cellular immunity in HLA-A2.1
transgenic mice
Giuseppina Di Mario1†, Bruno Garulli2†, Ester Sciaraffia1, Marzia Facchini1, Isabella Donatelli1 and Maria R. Castrucci1*
Abstract
Background: Cross-reactive immunity against heterologous strains of influenza virus has the potential to provide
partial protection in individuals that lack the proper neutralizing antibodies. In particular, the boosting of memory
CD8+ T cell responses to conserved viral proteins can attenuate disease severity caused by influenza virus antigenic
variants or pandemic strains. However, little is yet known about which of these conserved internal antigens would
better induce and/or recall memory CD8+ T cells after in vivo administration of an inactivated whole virus vaccine.
Methods: We explored the CD8 + T cell responses to selected epitopes of the internal proteins of an H7N3
influenza virus that were cross-reactive with A/PR/8/34 virus in HLA-A2.1 transgenic (AAD) mice.
Results: CD8+ T cells against dominant and subdominant epitopes were detected upon infection of mice
with live H7N3 virus, whereas immunization with non-replicating virus elicited CD8+ T cell responses against
mostly immunodominant epitopes, which were rapidly recalled following infection with A/PR/8/34 virus. These
vaccine-induced T cell responses were able to reduce the lung viral load in mice challenged intranasally with
the heterologous influenza virus.
Conclusions: A single immunization with non-replicating influenza virus vaccines may be able to elicit or
recall cross-reactive CD8+ T cell responses to conserved immunodominant epitopes and, to some extent,
counteract an infection by heterologous virus.
Background
Influenza A virus pandemics continue to occur sporadic-
ally in the human population. Moreover, the emergence
of a novel avian-origin reassortant influenza A (H7N9)
virus in China with several characteristic features of
mammalian influenza viruses poses concern for public
health [1]. Currently, vaccination using inactivated influ-
enza virus preparations remains the primary method of
prevention, especially for pre-pandemic vaccines. In par-
ticular, A/PR/8/34 (PR8)-based pre-pandemic vaccine
candidates, which contain the internal gene segments of
PR8 virus and the HA and NA genes from avian influ-
enza viruses with pandemic potential, have been gener-
ated and in some cases improved with respect to their
growth characteristics [2, 3]. However, while vaccine-
elicited antibodies will fully protect against homologous
virus infection, eventually they offer only marginal pro-
tection against heterologous drift virus infection.
Although heterosubtypic immunity in humans appears
to be weak, there is evidence that cross-reactive cell-
mediated immune responses contribute to disease control
[4–8]. Thus, vaccine-induced primary and memory re-
sponses by T cells against the relatively conserved internal
antigens of influenza could play an important role in redu-
cing the severity of disease caused by antigenic variants
that could arise [9–13]. Although non-replicating influ-
enza virus-based vaccines are known to be poor inducers
of cytotoxic T cell (CTL) responses, advances in the field
of adjuvants, delivery systems, and novel vaccination strat-
egies hold promise for improving their potential effective-
ness [14–17]. Inactivated whole virus vaccines with intact
membrane fusion activity are known to facilitate cross-
presentation to CD8+ T cells by antigen presenting cells
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(APC), and are more immunogenic than split vaccines
[18, 19]. Moreover, gamma-ray-inactivation of whole-virus
vaccines has been reported to preserve antigenicity, as
well as cellular and humoral immunogenicity, to a greater
extent than current viral inactivation methods [20]. Des-
pite the important role that multiple antigenic determi-
nants of internal viral proteins may have in protection
against infection, little is yet known about which of these
antigens would better induce and/or recall memory CD8+
T cells after in vivo administration of an inactivated whole
virus vaccine.
Because of different HLA haplotypes and MHC Class
I-dependent CD8+ T cell functions, the quality and
quantity of a T cell response can vary greatly between
individuals. HLA-A*0201 is an allele expressed by nearly
half of the world’s population and several studies have
been performed to determine the HLA-A2-restricted
CD8+ T cell responses following natural influenza virus
infection [21, 22]. In the present study, we investigated
the HLA-A*0201-restricted epitope specificities of CD8+
T cells in HLA-A2.1 transgenic (AAD) mice responding
to a non-replicating H7N3 whole virus, and revealed the
breadth of recall responses following infection of these
mice with heterologous PR8 virus. We also determined
whether these vaccine-induced virus-specific CD8+ T
cells, which target the internal conserved viral proteins,
affected virus replication in the lungs of the mice.
Methods
HLA-A2.1 transgenic mice
AAD mice were obtained from The Jackson Laboratory
(Bar Harbor, ME, USA). These mice with the C57BL/6J
genetic background express an interspecies hybrid class I
molecule, composed of the alpha 1 and alpha 2 domains
of the human HLA-A*0201 allele and the alpha 3, cyto-
plasmic and transmembrane domains of the mouse H-
2Dd class I molecule [23]. Female mice were used at 8–10
weeks of age; genetic authenticity was confirmed by
performing PCR for the transgene. All mice were main-
tained at Istituto Superiore di Sanità following institu-
tional guidelines and were used under approved protocols.
Peptides
The H2-Db restricted NP366 peptide and thirteen peptides
that bind the HLA-A2.1 molecule and are conserved
among diverse influenza subtypes were synthesized by
Primm (Italy). Peptide purity was >90 % in all cases, and
the identity of the peptides was verified by using spec-
trometry. The peptides were dissolved in DMSO at
10 mg/ml and stored at -20 °C.
Generation of PR8-NPN370Q virus
The mutant recombinant virus PR8-NPN370Q, in which
the asparagine at the fifth position of the epitope was
replaced with glutamine (N370Q), was generated by
using plasmid-driven reverse genetics, as described by
Neumann et al. [24]. The presence of the NP muta-
tion was confirmed by sequencing PCR-amplified
cDNA.
Immunization of mice and challenge experiments
Groups of AAD mice were injected intraperitoneally (i.p.)
with 500 HAU (approximately 3.5 μg of viral protein in a
0.5-ml volume) of either live or heat-inactivated (HI) low
pathogenic A/turkey/Italy/214845/02 virus (HI-H7N3).
Heat inactivation of small volumes of virus suspension
was performed in a water bath at 56 °C for 30 min and
confirmed by the complete loss of infectivity of MDCK
cells. Intranasal (i.n.) immunization was performed by an-
esthetizing mice with Avertin (2,2,2-tribromoethanol) and
then inoculating them with 102.4 TCID50 of PR8 virus,
resuspended in 40 μl of PBS. For the viral challenge,
mice in groups of 7 were i.n. infected with 3 LD50
(50 % lethal dose), corresponding to 103.7 TCID50 in a
volume of 40 μl, of PR8-NPN370Q virus. Naïve mice
were included as a negative control. The mice were
weighted daily and monitored for mortality for two
weeks. To determine viral lung titers, mice were sacri-
ficed 3 and 7 days post-infection (p.i.), and lung ho-
mogenates were titrated in MDCK cells. The limit of
viral detection was 0.5 log10 TCID50/ml.
IFN-γ ELISPOT assays
Spleens of mice (5–7 mice per group) were collected at
the indicated time points and assayed for antigen-specific
IFN-γ-producing cells by using an IFN-γ ELISPOT assay.
In the challenge experiments, inflammatory cells were also
collected from the lymph nodes draining the respiratory
tracts (mediastinal lymph nodes, MLN), lungs and bron-
choalveolar lavages (BAL) of infected mice as previously
described, and then directly subjected to the ELISPOT
assay [25, 26]. Single-cell suspensions from the lympho-
cytic populations were cultured with the indicated syn-
thetic peptides or DMSO in anti-IFN-γ-coated plates at
37 °C for 36–40 h. Colored spots representing IFN-γ-
releasing cells are reported as the number of spot-forming
cells (SFC) per 106 cells.
Serology
Serum samples were collected from mice vaccinated with
HI-H7N3 immediately before and 7 days after challenge,
and tested for the presence of influenza-specific antibodies
by using an hemagglutination–inhibition (HI) assay and a
micro-neutralization (MN) assay, as described previously
[27]. Sera were also tested in ELISA, using purified whole
inactivated viruses [28].
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Statistics
The statistical significance of the differences between
groups of animals was determined by using the Wilcoxon-
Mann-Whitney test; P < 0.05 was considered significant.
Results
Induction of influenza-specific CD8+ T cell responses in
AAD mice following vaccination with H7N3 virus
The initial experiments were designed to determine the
breadth and specificity of primary CD8+ T cell responses
that were elicited against the internal viral proteins in AAD
mice following i.p. immunization with the same dose of live
or HI-H7N3 virus. To this end, a panel of influenza-derived
CD8+ T cell epitope peptides (see Table 1), consisting of 1
nucleoprotein (NP) epitope, 10 polymerase epitopes, and 2
matrix (M1) epitopes, was used in IFN-γ ELISPOT assays
because they are highly conserved among different influ-
enza subtypes. These CD8+ T cell epitopes were previously
reported to be generated by natural processing of influenza
antigens in HLA-A2+ donors and were found to be im-
munogenic following subcutaneous injection of HLA-A2/
Kb transgenic mice [21, 22, 29].
Although the intramuscular or intranasal route is used
for vaccination in humans, the i.p. route of viral inocula-
tion does not permit productive influenza replication in
mice, and it is used to examine CD8+ T cell responses in
many studies performed in murine models of influenza
virus infection [30–32]. When mice were injected i.p.
with the live H7N3 virus, all the selected peptides contain-
ing dominant and subdominant T cell epitopes stimulated
IFN-γ secretion from mouse splenocytes in ex vivo ELI-
SPOT assays (Fig. 1a). In particular, a strong CD8+ T cell
response to the HLA-A2-restricted immunodominant
M158 epitope was observed in all mice. This is in accord-
ance with previous studies in AAD mice showing that
CTL recognition of the M158 peptide in the context of the
alpha 1 + alpha 2 domains was greatly augmented by re-
placing the human alpha 3 domain with its murine coun-
terpart in the transgenic class I molecule [23]. The
immunodominant peptide epitope NP366 was also in-
cluded in the assay to document the H2-Db-restricted
CD8+ T cell response that has always been observed in
these AAD transgenic mice with the C57BL/6J genetic
background [33]. Interestingly, the responses specific to
peptide epitope H2-Db-PA224 were weaker in these mice
compared with the co-dominant CD8 reactivity with
the H2-Db-NP366 epitope that has previously been
measured in C57BL/6J mice following primary virus
infection (data not shown and [34]). Similar reactivity
to H2-Db-PA224 was also measured with the overlap-
ping PA225 peptide epitope, which was recognized by
memory CD8+ T cells in A2+ healthy donors [22].
Table 1 Influenza A virus-derived MHC class I restricted T cell
epitopes included in the study
Peptides Sequence Position MHC restriction
M1-58 GILGFVFTL 58–66 HLA-A2.1
M1-59 ILGFVFTLTV 59–68 HLA-A2.1
PB1-407 MMMGMFNML 407–415 HLA-A2.1
PB1-413 NMLSTVLGV 413–421 HLA-A2.1
PB1-501 FVANFSMEL 501–509 HLA-A2.1
PB1-505 FSMELPSFGV 505–514 HLA-A2.1
PB2-49 WMMAMKYPI 49–57 HLA-A2.1
PB2-50 MMAMKYPITA 50–59 HLA-A2.1
PA-46 FMYSDFHFI 46–54 HLA-A2.1
PA-86 RTMAWTVVNSI 86–96 HLA-A2.1
PA-225 SLENFRAYV 225–233 HLA-A2.1
PA-282 FLLMDALKL 282–290 HLA-A2.1
NP-329 QLVWMACHSAA 329–339 HLA-A2.1
NP-366 ASNENMETM 336–374 H2-Db
Fig. 1 HLA-A2-restricted influenza-specific CD8 + T cell responses in
AAD mice. Groups of AAD mice (5/group) were immunized i.p. with
500 HAU of live (a) or heat-inactivated (HI)-H7N3 virus (b). Twelve
days later, influenza-specific CD8+ T cell responses were measured
in cells from freshly isolated splenocytes of individual mice by use
of an ex vivo IFN-γ-ELISPOT assay with the indicated peptides. Bars
represent means ± standard deviation (SD) for five mice per group.
The data are representative of three independent experiments
that gave similar results
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For this reason, the murine peptide epitope H2-Db-
PA224 was not included in the analysis.
In contrast to the live viral infection, mice immunization
with HI-H7N3 virus, which maintains fusion activity, elic-
ited CD8+ T cell responses that were mainly directed at
immunodominant epitopes M158 and H2-D
b-NP366. Re-
producible T cell responses were also observed for the
overlapping peptide M159, whereas undetectable or lower
numbers (50–80 SFC/106 cells) were consistently mea-
sured for the other subdominant epitopes, compared with
those measured in mice infected with live virus (Fig. 1b).
Together, these data indicate that a broad repertoire of
CD8+ T cell specificities are elicited in AAD mice upon
i.p. injection of live influenza virus, and that vaccination
with non-replicating H7N3 virus narrows the immune
response to the immunodominant epitopes.
Induction of CD8+ T cell recall responses to internal viral
proteins in mice immunized with HI-H7N3 virus and then
infected with PR8 virus
To further investigate the immunogenicity of whole
inactivated virus vaccines, mice were vaccinated with
HI-H7N3 virus and, one month later, i.n. infected with a
sublethal dose of PR8 virus. Then, virus-specific CD8+ T
cell responses were examined on day 7 p.i. by measuring
IFN-γ production from splenocytes in an ELISPOT assay
in the presence of the above-mentioned peptides. Primary
infection of control mice with PR8 virus induced CD8+ T
cell responses to the immunodominant H2-Db-NP366
and M158 epitopes and to other HLA-A2 restricted
subdominant epitopes (Fig. 2a). When mice were vac-
cinated with HI-H7N3 prior to PR8 virus infection,
the frequencies of immunodominant epitopes increased at
least 3-fold in the spleens, whereas the frequencies of the
subdominant epitopes were similar to those observed in
unvaccinated mice (Fig. 2b).
These results provide further evidence that HI-H7N3
virus could prime CD8+ T cell responses specific to the
immunodominant T cell epitopes that were rapidly recalled
following viral infection.
Induction of influenza-specific CD8+ T cell responses
by vaccination with HI-H7N3 virus in the presence of
pre-existing immunity to influenza virus
We next sought to determine whether prior exposure of
mice to a heterologous influenza virus affected the im-
munogenicity of the HI-H7N3 vaccine. Groups of mice
were i.n. primed with sublethal doses of PR8 virus, and
then six weeks later vaccinated i.p. with the HI-H7N3
virus. As shown in Fig. 3, the HI-H7N3 virus boosted
the CD8+ T cell responses specific to the immunodomi-
nant epitopes in the presence of pre-existing immunity
to influenza. Specifically, a 3- to 5-fold increase was
measured for the dominant M158 and H2-D
b-NP366
peptides, relative to the mice that received only the PR8
virus, whereas the frequency of the immune effectors
specific to the subdominant epitopes was at a similar
low level in both groups of mice, regardless of pre-
existing host immunity to the virus. Overall, these data
show that the inactivated whole virus vaccine could
induce recall responses to the H2-Db-NP366 and M158-
specific epitopes.
Virus load in the lungs of HI-H7N3 virus-vaccinated mice
upon challenge with a heterologous influenza virus
Previous studies have shown the protective efficacy of
M158-specific CD8+ T cells against virus infection in
HLA-A2 mice [35, 36]. Our results suggest that the
CD8 + T cell cross-reactivity between the internal pro-
teins of PR8 virus and the non-replicating HI-H7N3
vaccine in AAD mice involves the M158 and H2-D
b-
NP366 epitopes. To evaluate whether the M158-specific T
cells elicited by HI-H7N3 may play a role in protection
Fig. 2 HLA-A2-restricted influenza recall responses in mice immunized
with HI-H7N3 virus and then infected with PR8 virus. Naïve mice (a) or
mice vaccinated with HI-H7N3 virus 4 weeks earlier (b) (5/group) were
challenged i.n. under anesthesia with 102.4 TCID50 of PR8. Seven days
after challenge, mice were sacrificed and influenza-specific CD8+ T cell
responses were measured in cells from freshly isolated splenocytes of
individual mice by means of an ex vivo IFN-γ-ELISPOT assay with the
indicated peptides. Bars represent means ± SD for five mice per group.
The data are representative of two independent experiments that gave
similar results
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against challenge virus replication, we generated the re-
combinant influenza virus PR8-NPN370Q, in which the
anchor residue of the H2-Db-NP366 epitope that binds
the murine H2-Db MHC-I glycoprotein is mutated. This
mutation results in the absence of H2-Db-NP366 com-
plexes and a lack of CD8+ T cell recognition, that corre-
lates with a more severe disease, in spite of comparable
lung virus titers with those of mice infected with the
wild-type PR8 virus [31] (Fig. 4). We used this virus to
investigate whether cross-reactive CD8+ T cells could
limit the infection in mice vaccinated with HI-H7N3
virus and subsequently challenged with lethal doses of
PR8-NPN370Q virus. A single dose of a parenterally ad-
ministered vaccine was not capable to improve mouse
survival and weight loss in this viral challenge model
(data not shown). Nevertheless, the viral load in the
lungs of the immunized mice was reduced at 7 days post-
challenge by 20-to 40-fold compared with the control
mice (Fig. 5). A vigorous recall response of CD8+ T cells
targeting the M158 epitope was measured in the spleen of
these mice compared with the non-immunized mice.
Moreover, the recruitment of high levels of antigen-driven
IFN-γ-producing CD8+ cells to the airways and infected
lung by day 5 post-challenge suggests that the cross-
reactive M158-specific CD8+ T cells were likely respon-
sible for the reduced lung viral loads (Fig. 6a).
Fig. 3 Frequency of HLA-A2-restricted influenza specific CD8+ T cells
in AAD mice with pre-existing immunity to PR8 virus. Groups of naïve
mice (7/group) were infected i.n. under anesthesia with 102.4 TCID50 of
PR8 virus. Six weeks later, they were injected i.p. with PBS (a) or 500
HAU of HI-H7N3 virus (b). Nine days after vaccination, the mice were
sacrificed and influenza-specific CD8+ T cell responses were measured
in cells from freshly isolated splenocytes of individual mice by using an
ex vivo IFN-γ-ELISPOT assay with the indicated peptides. Bars represent
means ± SD for 7 mice per group. The data are representative of three
independent experiments that gave similar results
Fig. 4 Amino acid mutation in the H2-Db-NP366 epitope and CD8+
T cell recognition following virus infection in AAD mice. a Sequence
electropherograms showing the change from Asparagine (N) to
Glutamine (Q) at position 370 in the H2-Db-NP366 epitope of the
PR8-NPN370Q virus. b Mice were infected i.n. with 10
2.4 TCID50 of
PR8 or PR8-NPN370Q virus. Nine days later, the mice were sacrificed and
the frequency of H2-Db-NP366-specific IFN-γ-producing T cells was
measured by using an ELISPOT assay on spleen-derived lymphocytes
from individual mice. Results are expressed as means of triplicate
wells ± SD. The stained wells of representative samples are shown below
the graphical representations of the number of spot forming units (SFU)
per 106 cells
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Fig. 5 Viral load levels in the lungs of mice following infection with PR8-NPN370Q virus. Groups of mice (7/group) immunized with the HI-H7N3
virus were infected i.n. four weeks later with 3 LD50 (which corresponds to 10
3.7 TCID50) of PR8-NPN370Q virus. Naïve mice inoculated with PR8-NPN370Q
virus served as controls. Three days and seven days after challenge, mice were sacrificed and lungs were collected for viral titration on MDCK cells. Virus
titers from individual mice are presented as log10 TCID50 per ml (expressed as the mean ± SD log10TCID50/g of tissue). One of three similar experiments
is shown. *P < 0.005 compared with unprimed mice
Fig. 6 Quantification of M158-specific CD8 + T cells isolated from lung airways and lymphoid organs, and influenza-specific antibodies following
PR8-NPN370Q challenge. Groups of mice were treated as described in the legend for Fig. 5. a On day 5 or day 7 post-challenge, the mice were
sacrificed and the numbers of M158-specific CD8+ T cells were examined in the BAL, lungs, MLN, and spleen by using the IFN-γ-ELISPOT assay.
Results are expressed as means of triplicate wells ± SD. b & c Serum samples were drawn before (pre) and 7 days post-challenge (post) from
mice previously immunized with the HI-H7N3 virus, and specific antibodies against H7N3 and PR8 viruses were measured by HI (b) and ELISA (c); ELISA
for IgG antibodies; values for sera were obtained with use of 100-fold-diluted samples. ND = None detected. OD 450 = Optical density at 450 nm.
Values represent mean of 6 mice per group ± SD. One of three similar experiments is shown. *P < 0.05, NS = not significant, compared with
pre-challenge sera
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To exclude the possibility that cross-reactive anti-
bodies could also have contributed to this viral control,
pre-challenge sera obtained from mice that received the
HI-H7N3 vaccine, and post-challenge sera were analyzed
for the presence of influenza-specific antibodies. After
immunization with HI-H7N3 vaccine, mice developed
virus-specific antibodies that were detected by HI assay
that did not cross-react with PR8 virus (Fig. 6b). Similar
results were observed in the MN assay (data not shown).
When tested against detergent-disrupted viruses by
ELISA, pre-challenge sera as well as post-challenge sera
showed similar antibody levels against the H7N3 virus.
In contrast, only post-challenge sera showed high levels
of reactivity against the PR8 virus (Fig. 6c).
Overall, our results show that cross-protective cellular
immune responses can be induced in AAD mice following
systemic immunization with an inactivated whole-virus
influenza vaccine.
Discussion
In the present study, we evaluated CD8 +T cell responses
to internal viral proteins elicited by an inactivated H7N3
virus in AAD mice. We found that CD8+ T cell responses
to both the immunodominant epitopes and to most of the
highly conserved subdominant epitopes could be detected
in AAD mice upon inoculation with live virus, whereas
immunization with HI-H7N3 virus induced CD8+ T cell
responses mainly to the immunodominant epitopes. We
also found that the vaccine-induced T cell responses
appeared to reduce the lung viral load in mice challenged
with the PR8-NPN370Q virus, which lacks the H2-D
b-
NP366 epitope.
Most influenza-specific memory T cells that are detect-
able in humans are directed mainly against the remarkably
conserved epitopes of the internal viral proteins, and have
been reported to accumulate either as resident or central
memory T cells in the lungs and lymphoid tissues, respect-
ively, following recovery from influenza virus infections
[37–41]. Therefore, the rapid boosting of these cross-
reactive T cells in the respiratory tract by a pre-pandemic
vaccine could be extremely beneficial to provide protec-
tion against severe influenza virus infections [42]. Here,
the CD8 + T cell responses to the HLA-A2-restricted in-
fluenza epitope M158 paralleled those specific to the H2-
Db-NP366 epitope in AAD mice, following immunization
with live virus. Interestingly, the level of responses specific
to the H2-Db-PA224 epitope was lower in AAD mice than
in C57BL/6 mice. This low reactivity may reflect a re-
duced level of antigen-specific T cell precursors in AAD
mice, compared with the higher frequency of naïve pre-
cursors for H2-Db-PA224 than H2-D
b-NP366 in C57BL/6
mice [43]. Alternatively, it may be due to superior compe-
tition of T cells specific to the H2-Db-NP366 and M158
epitopes from the most abundant internal proteins during
antigen presentation.
In AAD mice immunized with a single dose of inacti-
vated H7N3 vaccine, CD8+ T cell responses were mainly
elicited by immunodominant epitopes. Several factors
contribute to the differences between live and inactivated
viruses in the CD8+ T cell response to the subdominant
epitopes. In particular, the provision of additional antigens
in the form of endogenously synthesized viral proteins,
following infection with a live virus, plays a key role. Our
results are consistent with those of other studies showing
that epitopes derived from more abundant viral proteins
contribute to immunodominant responses, although the
inherent features of the antigens and their capacity to be
cross-presented by APC also likely play a role [32, 44–46].
Likewise, others have reported that CTL induction by
cross-presentation of Lymphocytic Choriomeningitis virus
antigens, that were constitutively expressed in tumor cell
lines and injected in mice, was driven by immunodomi-
nant but not subdominant epitopes [47]. To further inves-
tigate the immunogenicity of the whole inactivated virus
vaccine, we used HI-H7N3 in a prime-boost approach
with live preparations of serologically distinct PR8 virus.
We detected and efficiently recalled, upon subsequent
viral infection, mainly CD8+ T cell responses that were re-
stricted to the immunodominant epitopes H2-Db-NP366
and M158, and the overlapping M159. Importantly, the
M158-specific CD8+ T cells were efficiently recruited to
the respiratory tract by subsequent i.n. infection with
PR8-NPN370Q virus, and were likely responsible for the re-
duction in lung viral load. Although we cannot exclude
that CD4+ and CD8+ T cells with other specificities may
help reduce viral infection, the lack of serum cross-
reactive antibodies further corroborates the most likely
protective effect of M158-specific CD8+ T cells. Neverthe-
less, no changes were observed in mortality of these mice
receiving a single dose of a parenterally administered vac-
cine as compared to unvaccinated mice. Our results agree
with other research findings showing that a subsequent
influenza virus infection in the respiratory tract is required
for reactivation of i.p. primed influenza virus-specific
CD8+ T cells and access to the lung airways [38, 48].
Indeed, activation and maintenance of T cell popula-
tions in the airways are dependent upon the route of
infection and prolonged presentation of viral antigens
in the lymph nodes draining the respiratory tract. Thus,
new immunization strategies that induce broadly cross-
reactive antibodies and T-cell responses at mucosal
surfaces could greatly improve influenza vaccine efficacy.
Although mouse models do not closely reflect human
influenza virus infection, yet our data suggest that a single
immunization with a whole inactivated influenza virus vac-
cine might also be able to elicit or recall cross-protective
immune responses specific to immunodominant NP and
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M epitopes in humans, and thus, to some extent, counter-
act an infection by an heterologous virus. In this context, it
would be interesting to explore the immunogenic pattern
and magnitude of the response elicited in the presence of
adjuvants or following immunization of these mice with
live, attenuated influenza vaccine (LAIV). Previous studies
have shown quantitative and qualitative differences in T
cell responses to LAIV and inactivated vaccines. In particu-
lar, viral replication of LAIV in the respiratory mucosa, es-
pecially of young children with low levels of pre-existing
immunity, provides better protection against infection,
likely due to a broader array of dominant and subdominant
T cell responses as well as beneficial induction of immune-
effectors at the site of infection [49, 50].
The M158 epitope is highly conserved among multiple
influenza viral strains and subtypes, and it is able to
elicit CTL responses in both HLA-A*02- and HLA-
C*08-positive individuals [29, 51]. Although functional
constraints on influenza virus CTL epitopes may limit
escape from CTL-mediated immunity, epitope mutations
may occur and, in some cases, these variant epitopes can
still be recognized, to some extent, by cross-reactive T
cells [52–54]. Indeed, CTL escape variants have been
shown to arise following independent amino acids muta-
tions either at the anchor residues or in the T cell recep-
tor contact residues of CTLs specific to the NP of
influenza A viruses isolated during circulation in human
populations [55, 56]. For these reasons, it is strongly de-
sirable to have more epitopes recognized by the immune
system to fight a viral infection. Furthermore, we cannot
exclude the possibility that inactivated whole virus-based
vaccines of avian origin would cross-react better than
PR8-based vaccines against new emerging zoonotic in-
fluenza viruses in human hosts. Although viral internal
proteins are highly conserved, the 10 %–15 % sequence
dissimilarity in the NP of different influenza subtypes,
for example, may be responsible for the loss of epitopes
of unknown HLA restrictions. Therefore, in the context
of inactivated vaccines against highly pathogenic influenza
strains that could arise from animal reservoirs, the recall
of dominant CD8+ T cell responses targeting the M and
NP proteins most closely related to the emerging virus
strains could be of great value in vaccine effectiveness.
Further studies are warranted to better characterize the
relationship between pre-existing CD8+ T-cell immunity
across the multiple ethnicities established in the human
population and epitope conservancy among the internal
proteins of potentially pandemic influenza strains [57].
Conclusion
In summary, our data show that a non-replicating whole
virus-based vaccine elicited cross-reactive influenza
virus-specific CD8+ T cell responses that were restricted
predominantly to immunodominant epitopes, and that
substantial numbers of effector-memory T cells were
recruited into the lungs of AAD mice for protection
against heterologous virus infection. Vaccination strategies
designed to improve the induction of or to boost immune
responses to the most conserved epitopes of newly emer-
ging influenza A virus strains would be extremely useful
for the development of pre-pandemic vaccines.
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